Universal Ibogaine Inc. (V:IBO)
Business Focus: N/A
Apr 12, 2024 06:00 am ET
Universal Ibogaine announces new private placement financing
Calgary, AB – TheNewswire -
April 12, 2024 – Universal Ibogaine Inc.
(TSXV:IBO) (“UI” or the “Company”), a life sciences company with a
mission to research and deliver medicalized ibogaine-centered
addiction care, advises that it intends to undertake a non-brokered
private placement offering of up to 30,000,000 common shares at a
price of $0.02 per share, for proceeds of up to $600,000 (the
“Offering”).
Apr 10, 2024 05:00 am ET
Apr 08, 2024 08:00 pm ET
Universal Ibogaine advises of management change
Calgary, AB – TheNewswire -
April 8, 2024 – Universal Ibogaine Inc.
(TSXV:IBO) (“UI” or the “Company”), a life sciences company with a
mission to research and deliver medicalized ibogaine-centered
addiction care, advises that Ian Rabb, Chief Clinics Officer, is no
longer with the Company. Mr. Rabb’s role with the Company’s
subsidiary, which operates the Kelburn Recovery Centre
(“Kelburn”) addiction treatment facility near Winnipeg, Manitoba,
will be assumed by Kerri Wilkinson, Clinic Manager, and Olga Shmelova,
Kelburn’s Clinical Director.
Feb 22, 2024 06:00 am ET
Universal Ibogaine Announces Additional Private Placement Financing
Calgary, AB – TheNewswire --
February 22, 2024 – Universal Ibogaine Inc.
(TSXV:IBO) (“UI” or the “Company”), a life sciences company with a
mission to deliver medicalized ibogaine-centered addiction care,
advises that it is undertaking a private placement offering of up to
80,000,000 common shares at a price of $0.01 per share (the
“Offering”) for proceeds of up to $800,000. The proceeds from the
Offering are intended to be used in the Company’s planned ibogaine
based clinical trial application process with Health Canada, and for
general working capital purposes.
Feb 07, 2024 06:00 am ET
Universal Ibogaine Advises of Closing of Private Placement Financing
Calgary, AB – TheNewswire -
February 7, 2023 – Universal Ibogaine Inc.
(TSXV:IBO) (“UI” or the “Company”), a life sciences company with a
mission to deliver medicalized ibogaine-centered addiction care, is
pleased to announce the closing of its previously announced (see news
release of December 20, 2023) non-brokered private placement (the
“Placement”) of common shares, and has issued 41,719,250 common
shares at a price of $0.01 per share for gross proceeds of
$417,192.
Feb 02, 2024 05:00 am ET
Jan 19, 2024 05:00 am ET
Universal Ibogaine provides Bi-weekly Default Status Report and update on status of Private Placement
Calgary, AB – TheNewswire -
January 19, 2024 – Universal Ibogaine Inc.
(TSXV:IBO) (“UI” or the “Company”), a life sciences company with a
mission to deliver medicalized ibogaine-centered addiction care,
provides the following bi-weekly default status report update:
Jan 05, 2024 05:00 pm ET
Universal Ibogaine provides Bi-weekly Default Status Report
Calgary, AB – TheNewswire --
January 5, 2024 – Universal Ibogaine Inc.
(TSXV:IBO) (“UI” or the “Company”), a life sciences company with a
mission to deliver medicalized ibogaine-centered addiction care,
provides the following bi-weekly default status report update:
Dec 20, 2023 11:00 pm ET
Universal Ibogaine Advises of Appointment of New Auditors and Private Placement
Calgary, AB – TheNewswire -
December 20, 2023 – Universal Ibogaine Inc.
(TSXV:IBO) (“UI” or the “Company”), a life sciences company with a
mission to deliver medicalized ibogaine-centered addiction care,
provides the following updates:
Dec 11, 2023 06:00 am ET
Universal Ibogaine Announces Granting of Management Cease Trade Order
Calgary, AB – TheNewswire -
December 11, 2023 – Universal Ibogaine Inc.
(TSXV:IBO) (“UI” or the “Company”), a life sciences company with a
mission to deliver medicalized ibogaine-centered addiction care,
advises that its application for a temporary management case trade
order (“MCTO”) has been granted by the Alberta Securities Commission
(the “ASC”, as Principal Regulator).
Dec 01, 2023 05:00 pm ET
Universal Ibogaine provides update on prior application for Management Cease Trade Order
Calgary, AB - TheNewswire - December 1, 2023 -
Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the
“Company”), a life sciences company with a mission to deliver
medicalized ibogaine-centered addiction care, advises of the following
update and revision to its prior news release which was issued on
November 20, 2023.
Nov 20, 2023 06:30 pm ET
Universal Ibogaine Advises of Application for Management Cease Trade Order
Calgary, AB – TheNewswire -
November 20, 2023 – Universal Ibogaine Inc.
(TSXV:IBO) (“UI” or the “Company”), a life sciences company with a
mission to deliver medicalized ibogaine-centered addiction care,
advises that it has made an application to the Alberta Securities
Commission (as Principal Regulator) and the British Columbia
Securities Commission, to approve a temporary management case trade
order (“MCTO”) under National Policy 12-203 - Cease Trade Orders for Continuous
Disclosure Defaults (“NP 12-203”), which,
if granted, will prohibit trading securities of the Company by the
Chief Execu
Oct 04, 2023 05:30 am ET
Universal Ibogaine Engages Mike "Zappy" Zapolin as a Strategic Advisor
Calgary, AB – TheNewswire -
October 4, 2023 – Universal Ibogaine Inc.
(TSXV:IBO) (“UI” or the “Company”), a life sciences company with a
mission to deliver medicalized ibogaine-centered addiction care, is
pleased to advise that it has engaged and retained Mike “Zappy”
Zapolin as a strategic and business development advisor.
Sep 06, 2023 08:00 pm ET
Universal Ibogaine Provides Corporate Update on Belize Property and Notice of Resignation of Auditors
Calgary, AB - TheNewswire - September 6, 2023 -
Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the
“Company”), a life sciences company with a mission to deliver
medicalized ibogaine-centered addiction care, provides the following
updates:
Jun 07, 2023 04:00 am ET
Universal Ibogaine Advises of Update on the Status of Proposed Sale of Belize Island Property
Calgary, AB – TheNewswire -
June 7, 2023 – Universal Ibogaine Inc.
(TSXV:IBO) (“UI” or the “Company”), a life sciences company with a
mission to deliver medicalized ibogaine-centered addiction care,
advises that it will not be closing its previously announced (see News
Release of March 30, 2023) agreement to sell its 20-acre undeveloped
island property located in Belize (the “Property”) for USD
1,300,000 on June 15, 2023 as was scheduled.
May 19, 2023 06:30 am ET
Universal Ibogaine Announces Offering of Common Shares
Calgary, AB – TheNewswire -
May 19, 2023 – Universal Ibogaine Inc.
(TSXV:IBO) (“UI” or the “Company”), a life sciences company with a
mission to deliver medicalized ibogaine-centered addiction care,
advises that it is undertaking an offering of up to 66,666,667 share
“Units” at a price of $0.03 per Unit (the “Offering”) for
proceeds of up to $2,000,000. Each Unit will consist of one common
share and a one-half common share purchase
warrant (a “Warrant”), with each whole Warrant allowing
the holder to acquire an additional UI common share at a fixed price
of $0.06 per share for a period of on
May 09, 2023 05:00 am ET
Universal Ibogaine announces changes to its Board of Directors and addition to Advisory Board
Calgary, AB – TheNewswire -
May 9, 2023 – Universal Ibogaine Inc.
(TSXV:IBO) (“UI” or the “Company”), a life sciences company with a
mission to deliver medicalized ibogaine-centered addiction care,
advises of the departure of two members of its Board of Directors (the
“Board”). Dr. Alberto Sola Agullo has decided to resign from
the Board in order to focus his time on his ibogaine based addiction
treatment business, Clear Sky Recovery Cancun SA de CV
(“Clear Sky”) which operates in Cancun, Mexico. In conjunction,
Robert Turner has also chosen to resign from the Board, which
continues with me
Apr 14, 2023 10:15 pm ET
TSX Venture Exchange Stock Maintenance Bulletins
VANCOUVER, BC, April 14, 2023 /CNW/ -
Apr 13, 2023 02:00 pm ET
Universal Ibogaine Announces Closing of Offering of Convertible Debt Securities
Calgary, AB – TheNewswire -
April 13, 2023 – Universal Ibogaine Inc.
(TSXV:IBO) (“UI” or the “Company”), a life sciences company with a
mission to deliver medicalized ibogaine-centered addiction care,
advises that it has processed a closing of $180,000 under its
previously announced (see News Release of March 16, 2023) offering of
convertible debt securities (the “Offering”). The
Offering consisted of “Secured Guarantee Convertible Notes” (the
“Notes”) which bear interest at 8% (payable quarterly), and have
a maturity of 3 years from the Closing of the
Offering. Closing of the Offering, and
Mar 30, 2023 07:00 am ET
Universal Ibogaine announces agreement for the sale of Belize island property
Calgary, AB – TheNewswire -
March 30, 2023 – Universal Ibogaine Inc.
(TSXV:IBO) (“UI” or the “Company”), a life sciences company with a
mission to deliver medicalized ibogaine-centered addiction care,
advises that it has reached an agreement (the “Offer”) to sell its
20-acre undeveloped island property located in Belize (the
“Property”) for USD 1,300,000. A summary of the terms of the sale
transaction follows:
Mar 16, 2023 08:00 pm ET
Universal Ibogaine Announces Revision to Terms of Offering of Convertible Debt Securities
Calgary, AB - TheNewswire - March 16, 2023 -
Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the
“Company”), a life sciences company with a mission to deliver
medicalized ibogaine-centered addiction care, advises that following
preliminary approval by the TSX Venture
Exchange (the “TSXV”), it has slightly
modified the terms of its pending offering of convertible debt
securities (the “Offering”, as was described in the
Company’s prior News Release of February 6, 2023).
Feb 06, 2023 07:00 am ET
Universal Ibogaine Announces Offering of Convertible Debt Securities
Calgary, AB – TheNewswire -
February 6, 2023 – Universal Ibogaine Inc.
(TSXV:IBO) (“UI” or the “Company”), a life sciences company with a
mission to deliver medicalized ibogaine-centered addiction care,
advises that it is in process of finalizing an offering of convertible
debt securities (the “Offering”). The Offering consists of up to
$5 million of “Secured Guarantee Convertible Notes” (the
“Notes”) which will bear interest at 8% (payable quarterly) and
have a maturity of 3 years from the Closing of
the Offering. Closing of the Offering, and the payment of any
finders fees related thereto
Jan 23, 2023 07:00 am ET
Universal Ibogaine Announces Re-Opening of the Kelburn Recovery Center
Calgary, AB – TheNewswire -
January 23, 2023 – Universal Ibogaine Inc.
(TSXV:IBO) (“UI” or the “Company”), a life sciences company with a
mission to deliver medicalized ibogaine-centered addiction care,
advises that it’s addiction and mental health treatment clinic, the
Kelburn Recovery Center (“Kelburn”), which operates near Winnipeg,
Manitoba via a wholly-owned subsidiary of UI, has re-opened effective
January 23, 2023.
Jan 04, 2023 08:52 am ET
Universal Ibogaine Highlights 2022 Accomplishments
Calgary, AB – TheNewswire -
January 4, 2023 – Universal Ibogaine Inc.
(TSXV:IBO) (“UI” or the “Company”), a life sciences company with a
mission to transform the addiction treatment industry with medicalized
ibogaine-centered care, is pleased to provide a year end summary of
2022 accomplishments.
Dec 09, 2022 12:00 pm ET
Universal Ibogaine Issues Common Shares Pursuant to Settlement of Claim
Calgary, AB – TheNewswire -
December 9, 2022 – Universal Ibogaine Inc.
(TSXV:IBO) (“UI” or the “Company”), a life sciences company with a
mission to deliver medicalized ibogaine-centered addiction care,
announces that it has agreed to issue 350,000 common shares (at a
deemed price of $0.05) as part of a settlement agreement related to a
claim filed in August 2021 by a former non-arm’s length consultant
to the Company. The shares issued will be subject to a hold period
of 4-months plus one day from the date of issuance, and the issuance
has been accepted by the TSX Venture Exchange.
Dec 01, 2022 01:34 pm ET
Universal Ibogaine Undertaking Offering of Convertible Debt Securities and Common Shares
Calgary, AB – December 1, 2022 – Universal Ibogaine
Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a
mission to deliver medicalized ibogaine-centered addiction care,
advises that it is in process of finalizing an offering (the
“Offering”) of convertible debt securities. The Offering will
consist of “Secured Guarantee Convertible Notes” (the
“Notes”) which will bear interest at 8% (payable quarterly) and
have a maturity of 3 years from the Closing of
the Offering. Closing of the Offering, and the payment of any
finders fees related thereto, is subject to the required a
Dec 01, 2022 01:20 pm ET
Universal Ibogaine Announces Closing of Private Placement
Copyright (c) 2022 TheNewswire - All rights reserved.
Nov 08, 2022 08:00 am ET
Universal Ibogaine Announces Formation of Advisory Board
Calgary, AB – TheNewswire - November 08, 2022 – Universal Ibogaine Inc.
(TSXV:IBO)
(“UI” or the
“Company”), a life
sciences company with a mission to deliver medicalized
ibogaine-centered addiction care, is pleased to announce the formation
of an external Advisory Board as part of its strategic plans and
mission to deliver medicalized ibogaine-centered addiction care and to
undertake a planned clinical trial application
process.
Oct 05, 2022 06:30 am ET
Universal Ibogaine Announces Results of Annual General Meeting
Calgary, AB – TheNewswire -
October 5, 2022 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the
“Company”), a life sciences company with a mission to deliver
medicalized ibogaine-centered addiction care, is pleased to announce
that all resolutions were passed by the requisite majority of
shareholders at its annual general meeting (“AGM”) which was
held on October 3, 2022 in Vancouver, BC.
Oct 03, 2022 02:37 pm ET
Universal Ibogaine Undertaking Offering of Convertible Debt Securities and Common Shares
Calgary, AB – TheNewswire -
October 3, 2022 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a
mission to deliver medicalized ibogaine-centered addiction care,
advises that it is in process of finalizing an offering (the
“Offering”) of convertible debt securities. The Offering will
consist of “Secured Guarantee Convertible Notes” (the
“Notes”) which will bear interest at 8% (payable quarterly) and
have a maturity of 3 years from the Closing of
the Offering. Closing of the Offering, and the payment of any
finders fees related thereto, is subject to t
Sep 26, 2022 03:01 pm ET
Universal Ibogaine Featured in Psychedelics Tonight Documentary Series
Calgary, AB – TheNewswire
- September 26, 2022 – Universal
Ibogaine Inc. (TSXV:IBO)
(“UI” or the “Company”), a life sciences company with a
mission to deliver medicalized ibogaine-centered addiction care, is
pleased to announce it has been featured in a documentary series
entitled Psychedelics
Tonight, which was co-produced by Kyle Buller
and Joe Moore of Psychedelics Today in partnership with ALTRD.TV.
The docuseries provides
information on the history and future potential of several psychedelic
compounds including iboga and ibogaine, with the first episode of the
series airing Monday Sept
Sep 21, 2022 05:54 pm ET
Universal Ibogaine Announces Kelburn Reopening Date
Calgary, AB – TheNewswire -
September 22, 2022 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the
“Company”), a life sciences company with a mission to deliver
medicalized ibogaine-centered addiction care, advises that it’s
research and development clinic, the Kelburn Mental Health and
Addiction Recovery Center is scheduled to reopen and commence business
operations on October 17, 2022 .
Sep 06, 2022 08:00 am ET
Universal Ibogaine appoints Nick Karos to the Board of Directors
Calgary, AB – TheNewswire -
September 6, 2022 – Universal Ibogaine Inc.
(TSXV:IBO) (OTC:IBOGF) (“UI” or the
“Company”), a life sciences company with a mission to deliver
medicalized ibogaine-centered addiction care, advises that it has
appointed Nicholas (“Nick”) Karos, CEO of the Company, to its
Board of Directors of UI effective September 6, 2022. UI will hold
its Annual Meeting of Shareholders in Vancouver on October 3, 2022,
and at that time the existing group of 5 Directors, including Mr.
Karos, will stand for election to the Board.
Aug 19, 2022 04:00 am ET
Universal Ibogaine Provides Update on Kelburn Recovery Center
Calgary, AB – TheNewswire -
August 19, 2022 – Universal Ibogaine Inc.
(TSXV:IBO) (OTC:IBOGF)
(“UI” or the “Company”) is a life
sciences company with a mission to deliver medicalized
ibogaine-centered addiction care. Ibogaine is a plant derived medicine
used in addiction treatment and has been shown to deliver
detoxification from opioids, heroin and other substances, and can
provide a several month window free of drug cravings.
Jun 24, 2022 01:42 pm ET
Nick Karos to Present at H.C. Wainwright 1st Annual Mental Health Conference
Calgary, AB – TheNewswire -
June 24, 2022 – Universal Ibogaine Inc. (TSXV:IBO),
(OTC:IBOGF) and
(FSE:JC4) (“UI” or the “Company”) a life sciences company with a mission to
transform addiction treatment using medicalized ibogaine and a global
licensing model is pleased to announce that Nick Karos, CEO will
present at the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry,
Psychedelics and Beyond. The event is a hybrid online and in person
event scheduled for June 27, 2022.
Jun 13, 2022 04:20 pm ET
UNIVERSAL IBOGAINE Engages Investor Relations Firm Blue Digital Media
Calgary, AB – TheNewswire
- June 13, 2022 – Universal Ibogaine Inc. (TSXV:IBO),
(OTC:IBOGF) and
(FSE:JC4) (“UI” or the “Company”) a life sciences company with a mission to
transform addiction treatment through the use of medicalized ibogaine
and a global licensing model advises it has engaged investor
communications firm Blue Digital Media & Web Solutions
(“Blue
Digital”) for assistance
with expanding awareness of UI’s business activities.
Jun 10, 2022 06:50 pm ET
Universal Ibogaine Advises of Departure of David Danziger from the Board of Directors
Calgary, AB – TheNewswire -
June 10, 2022 – Universal Ibogaine Inc.
(TSXV:IBO) (“UI” or the “Company”) a life sciences company with a
mission to develop and deliver medicalized ibogaine-centered addiction
care, advises that David Danziger has resigned as a member of the UI
Board of Directors.
May 13, 2022 02:00 pm ET
Universal Ibogaine Co-Founder Dr Alberto Sola to Present at upcoming Research to Reality Conference
CALGARY, AB, May 13, 2022 /PRNewswire/ - Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) ("UI" or the "Company") a life sciences company with a mission to transform addiction treatment through the use of medicalized ibogaine and a global licensing model is pleased to announce that UI Co-Founder Dr Alberto Sola will present at the May 27 to 29 event: From Research to Reality: Global Summit on Psychedelic Assisted Therapies and Medicine which will be held in Toronto, Canada from May 27 to 29, 2022.
May 13, 2022 02:00 pm ET
Universal Ibogaine Co-Founder Dr Alberto Sola to Present at upcoming Research to Reality Conference
CALGARY, AB, May 13, 2022 /CNW/ - Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) ("UI" or the "Company") a life sciences company with a mission to transform addiction treatment through the use of medicalized ibogaine and a global licensing model is pleased to announce that UI Co-Founder Dr Alberto Sola will present at the May 27 to 29 event: From Research to Reality: Global Summit on Psychedelic Assisted Therapies and Medicine which will be held in Toronto, Canada from May 27 to 29, 2022.
Apr 29, 2022 12:00 pm ET
UNIVERSAL IBOGAINE RETAINS SHAYNE NYQUVEST AS CAPITAL MARKETS ADVISOR
CALGARY, AB, April 29, 2022 /PRNewswire/ - Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) ("UI" or the "Company") a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, advises that it has retained Mr. Shayne Nyquvest in a consulting role as Capital Markets Advisor.
Apr 29, 2022 12:00 pm ET
UNIVERSAL IBOGAINE RETAINS SHAYNE NYQUVEST AS CAPITAL MARKETS ADVISOR
CALGARY, AB, April 29, 2022 /CNW/ - Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) ("UI" or the "Company") a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, advises that it has retained Mr. Shayne Nyquvest in a consulting role as Capital Markets Advisor.
Apr 21, 2022 12:00 pm ET
Universal Ibogaine Advises of Departure of Marilyn Loewen Mauritz from the Board of Directors
Calgary, AB – TheNewswire -
April 21, 2022 – Universal Ibogaine Inc.
(TSXV:IBO) (“UI” or the “Company”) a life sciences company with a
mission to develop and deliver medicalized ibogaine-centered addiction
care, advises that Marilyn Loewen Mauritz has resigned as a member of
the UI Board of Directors to pursue other opportunities.
Apr 07, 2022 08:01 pm ET
UNIVERSAL IBOGAINE PROVIDES UPDATE ON KELBURN RECOVERY CENTER OPERATIONS
CALGARY, AB, April 7, 2022 /PRNewswire/ - Universal Ibogaine Inc. (TSXV: IBO) ("UI" or the "Company") a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, advises that it has temporarily closed the Kelburn Recovery Centre ("Kelburn") due to an on-site flooding issue.
Apr 07, 2022 08:01 pm ET
UNIVERSAL IBOGAINE PROVIDES UPDATE ON KELBURN RECOVERY CENTER OPERATIONS
CALGARY, AB, April 7, 2022 /CNW/ - Universal Ibogaine Inc. (TSXV: IBO) ("UI" or the "Company") a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, advises that it has temporarily closed the Kelburn Recovery Centre ("Kelburn") due to an on-site flooding issue.
Apr 06, 2022 07:00 am ET
Universal Ibogaine Announces Frankfurt Stock Exchange Listing
CALGARY, AB, April 6, 2022 /PRNewswire/ - Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) ("UI" or the "Company") a life sciences company with a mission to transform the world of addiction treatment through medicalized ibogaine and a state of the art ongoing care program, is pleased to announce that its common shares have been approved for trading on the Frankfurt Stock Exchange, or Bourse Frankfurt (the "FSE") under the ticker symbol "JC4". UI will continue to trade in Canada on the TSX Venture Exchange under its current ticker symbol IBO and on the OTCQB under the ticker sym
Apr 06, 2022 07:00 am ET
Universal Ibogaine Announces Frankfurt Stock Exchange Listing
CALGARY, AB, April 6, 2022 /CNW/ - Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) ("UI" or the "Company") a life sciences company with a mission to transform the world of addiction treatment through medicalized ibogaine and a state of the art ongoing care program, is pleased to announce that its common shares have been approved for trading on the Frankfurt Stock Exchange, or Bourse Frankfurt (the "FSE") under the ticker symbol "JC4". UI will continue to trade in Canada on the TSX Venture Exchange under its current ticker symbol IBO and on the OTCQB under the ticker symbol IBO
Mar 24, 2022 07:29 am ET
Universal Ibogaine to Participate in the 2022 Virtual Growth Conference - Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT
CALGARY, AB, March 24, 2022 /CNW/ - Universal Ibogaine (TSXV: IBO) (OTCQB: IBOGF), a life sciences company with a mission to transform the world of addiction treatment through medicalized ibogaine and a state of the art ongoing care program, announced today that Company CEO Nick Karos has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.
Mar 23, 2022 07:00 am ET
UNIVERSAL IBOGAINE EXPANDS RESEARCH TEAM WITH JULIE DUMOUCHEL, DIRECTOR OF CLINICAL TRIALS
CALGARY, AB, March 23, 2022 /CNW/ - Universal Ibogaine Inc. (TSXV: IBO) and (OTCQB: IBOGF) ("UI" or the "Company") a life sciences company with a mission to transform the world of addiction treatment through medicalized ibogaine and a state of the art ongoing care program, is pleased to announce the key strategic addition of Julie Dumouchel as Director of Clinical Trials. Universal Ibogaine is working towards a planned clinical trial with Health Canada to prove the safety and efficacy of ibogaine for the disruption of opioid addiction. UI owns the global licensing rights for the ibogaine t
Mar 08, 2022 07:00 am ET
Universal Ibogaine Inc. to Webcast Live at OTC Markets VirtualInvestorConferences.com March 10th
Universal Ibogaine (OTCQB:IBOGF) (TSX-V:IBO) (FSE:JC4), a life sciences company based in Canada, focused on transforming the addiction treatment industry through the medical use of the plant medicine ibogaine, today announced that Nick Karos Name,...
Mar 07, 2022 08:35 am ET
Life Sciences Virtual Investor Conference: Company Executives Present Live March 10th
Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Investor Forum on March 10th. This virtual event will showcase live company presentations and interactive...
Feb 28, 2022 06:00 am ET
Universal Ibogaine Announces Approval for Trading on the OTCQB Venture Market
CALGARY, AB, Feb. 28, 2022 /CNW/ - Universal Ibogaine Inc. (TSXV:IBO ) (OTCQB: IBOGF) ("UI" or the "Company") a life sciences company with a mission to transform the world of addiction treatment through medicalized ibogaine and a state of the art ongoing care program, is pleased to announce that its common shares have been approved for trading on the OTCQB Venture Market (the "OTCQB") under the ticker "IBOGF". UI will continue to trade in Canada on the TSX Venture Exchange under its current ticker symbol IBO. The UI common shares trading in the United States have also been approved for DTC
Jan 26, 2022 06:00 am ET
UNIVERSAL IBOGAINE ENTERS DRUG SUPPLY AGREEMENT
CALGARY, AB, Jan. 26, 2022 /CNW/ - Universal Ibogaine Inc. (TSXV: IBO) ("UI" or the "Company") a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, is pleased to advise it has entered into an agreement (the "agreement") with Psygen Labs Inc. ("Psygen") to secure a supply of GMP ibogaine for use in its planned future clinical trial for opioid use disorder and ongoing ibogaine detox treatments at its clinics.
Jan 19, 2022 08:06 am ET
Kelburn Mental Health & Addiction Treatment Centre Announces New Ownership, New Leadership and New Modalities
WINNIPEG, MB, Jan. 19, 2022 /CNW/ - Kelburn Recovery Centre is pleased to announce that Dr. Ian Rabb, addiction treatment and clinic operations veteran has recently joined as Managing Director.
Jan 14, 2022 06:00 am ET
UNIVERSAL IBOGAINE ANNOUNCES WORLD-CLASS CLINICAL TRIAL PARTNERS IN ADVANCE OF CLINICAL TRIAL APPLICATION OR IBOGAINE IN OPIOID USE DISORDER
CALGARY, AB, Jan. 14, 2022 /CNW/ - Universal Ibogaine Inc. (TSXV: IBO) ("UI" or the "Company") a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, is pleased to introduce its contract research organization ("CRO") partners who will enable UI's planned clinical trial in Canada to be conducted, subject to the required approval by Health Canada. UI is currently working with its CRO partners to finalize UI's study design in advance of an anticipated pre-clinical trial application meeting to soon be held with Health Canada.
Jan 11, 2022 05:45 pm ET
The Power Play by The Market Herald Releases Interviews With Reyna Gold, Universal Ibogaine, NewRange Gold, Fabled Copper, and Fandom Sports Media
VANCOUVER, BC / ACCESSWIRE / January 11, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Reyna Gold, Universal Ibogaine, NewRange Gold, Fabled Copper, and Fandom Sports Media discussing their latest press releases.
Jan 09, 2022 11:00 pm ET
Universal Ibogaine Announces Change in Leadership
Calgary, AB - TheNewswire
- January 10, 2022 - Universal Ibogaine Inc.
(TSXV:IBO) (“UI” or the “Company”) announces that Rami Batal has been replaced as Chief
Executive Officer (“CEO”) of the Company and its subsidiaries.
For the present time, the Company has appointed Nick Karos as CEO,
effective immediately. Mr. Karos had recently been appointed as a
Capital Markets consultant to the Company.
Dec 02, 2021 03:30 pm ET
Universal Ibogaine Announces Expansion of Executive Team andGrant of Stock Options
Calgary, AB - TheNewswire – December 2, 2021 –
Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the
“Company”), a life sciences company with a mission to research and
deliver medicalized ibogaine-centered addiction care, is pleased to
announce an expansion of its’ Executive team, and welcomes Nick
Karos as its new Director – Capital Markets.
Nov 05, 2021 04:10 pm ET
The Power Play by The Market Herald Releases New Interviews with Universal Ibogaine and Hank Payments on Their Latest News
VANCOUVER, BC / ACCESSWIRE / November 5, 2021 / The Power Play by The Market Herald has announced the release of new interviews with Universal Ibogaine and Hank Payments discussing their latest press releases.
Nov 04, 2021 08:00 am ET
Universal Ibogaine Announces Chief Clinics Officer Dr Ian Rabb
CALGARY, AB, Nov. 4, 2021 /CNW/ - Universal Ibogaine Inc. (TSXV: IBO) ("Universal Ibogaine", "UI" or the "Company"), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, is pleased to announce an expansion of its Executive Team and welcomes addiction treatment and clinic operations veteran Dr Ian Rabb as Chief Clinics Officer effective November 15, 2021.
Oct 25, 2021 10:00 am ET
Universal Ibogaine Announces Engagement of Media and Investor Relations Advisors
Calgary, AB – TheNewswire -
October 25, 2021 – Universal Ibogaine Inc.
(TSXV:IBO) (“UI”
or the
“Company”), a life sciences company with a
mission to research and deliver medicalized ibogaine-centered
addiction care, advises that it has retained three additional advisors
as part of the expansion of its’ market
awareness and investor relations program.
Oct 21, 2021 06:00 pm ET
Universal Ibogaine Announces Engagement of Investor Relations Advisor
Calgary, AB – TheNewsire - October 21, 2021 –
Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and
deliver medicalized ibogaine-centered addiction care, advises that it
has retained Volume Hunters Ltd. (“Volume Hunters”)
of Vancouver, Canada, as an enhancement of its’ investor relations
program.
Oct 19, 2021 08:45 am ET
Universal Ibogaine Announces Enhancement of Board of Directors
Calgary, AB – TheNewswire -
October 19, 2021 – Universal Ibogaine Inc.
(TSXV:IBO) (“Universal Ibogaine”, “UI” or the “Company”),
a life sciences company with a mission to research and deliver
medicalized ibogaine-centered addiction care, is pleased to announce
an expansion of its Board of Directors and welcomes two seasoned
public company Board veterans, Anthony DeCristofaro and David
Danziger, to fill two current Board vacancies.
Oct 05, 2021 06:30 am ET
Universal Ibogaine Commences Trading on the TSX-V
Calgary, AB – TheNewswire - October 5, 2021 – Universal Ibogaine Inc.
(TSXV:IBO) (“Universal Ibogaine”, “UI” or the “Company”),
a life sciences company with a mission to
deliver medicalized ibogaine-centered addiction care, is pleased to
announce the commencement of trading today of its common shares on the
TSX Venture Exchange (“TSXV”) under the symbol “IBO”.
Oct 04, 2021 05:21 pm ET
IIROC Trading Resumption - IBO
VANCOUVER, BC, Oct. 4, 2021 /CNW/ - Trading resumes in:
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
